financetom
Business
financetom
/
Business
/
Update: Titan Mining Up Nearly 5% as It Swings to Q1 Profit as Revenue Rises 37%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Titan Mining Up Nearly 5% as It Swings to Q1 Profit as Revenue Rises 37%
May 26, 2025 7:54 AM

11:49 AM EDT, 05/14/2025 (MT Newswires) -- (Updates shares.)

Titan Mining ( TIMCF ) on Wednesday said it swung to a first-quarter profit as revenue grew by 37%.

Net income came in at US$0.35 million, or nil per share, swinging from a loss of US$2.6 million, or US$0.02 per share. Revenue rose to US$16 million from US$11.7 million.

The company produced 15.4 million pounds of payable zinc, up 5% from 14.7 million pounds.

"With zinc operations delivering robust cash flow and our graphite project advancing rapidly, we are executing on our dual-commodity growth plan and positioning Titan as a reliable U.S. supplier of critical minerals," said Titan President Rita Adiani.

Titan shares were last seen up $0.03 to $0.64 on the Toronto Stock Exchange.

Price: 0.64, Change: +0.03, Percent Change: +4.92

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Wednesday it has started a phase 2 study of ALTO-203 in major depressive disorder patients. Alto said it expects to enroll about 60 adult participants with MDD and anhedonia, with top-line data expected in H1 of 2025. The company said ALTO-203 showed a favorable tolerability profile across...
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Merck ( MRK ) and Daiichi Sankyo said Wednesday they have dosed the first patient in a phase 2/3 trial assessing the efficacy and safety of investigational drug raludotatug deruxtecan to potentially treat ovarian cancer resistant to platinum-based chemotherapy. The second phase of the study is being done to establish the dose of...
Factbox-US, Canadian companies kick off 2024 with layoffs
Factbox-US, Canadian companies kick off 2024 with layoffs
Apr 3, 2024
(Reuters) -Companies in the United States and Canada have kicked off 2024 with thousands of job cuts across sectors, signaling that the spate of layoffs seen in 2023 could persist as they scramble to rein in costs. While hopes of a soft landing have grown in recent months, companies continue to be cautious as the outlook on rate cuts by...
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Asensus Surgical ( ASXC ) shares jumped more than 28% in recent trading after the company said Wednesday that it has entered into a non-binding letter of intent with medical technology company KARL STORZ for a potential acquisition of Asensus. Asensus said that the letter of intent includes the proposal to acquire all...
Copyright 2023-2026 - www.financetom.com All Rights Reserved